Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723099 · ClinicalTrials.gov registry record · Phase 2
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
A Phase 2 study of Lymphoma and Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 6
- Study locations
NCT00723099 is a Phase 2 study of Lymphoma and Acute Myeloid Leukemia that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 73 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00723099, a Phase 2 study of Lymphoma and Acute Myeloid Leukemia, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- OTHER Laboratory Biomarker Analysis
- DRUG Fludarabine Phosphate
- DRUG Cyclosporine
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
Study Locations (6)
Colorado
- University of Colorado Hospital - Aurora
- Colorado Blood Cancer Institute - Denver
Washington
- VA Puget Sound Health Care System - Seattle
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Utah
- LDS Hospital - Salt Lake City
Wisconsin
- Froedtert and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2008-06-25 |
| Est. Completion | 2018-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723099
The ClinicalTrials.gov registry entry for NCT00723099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00723099 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Washington, Utah.
Frequently Asked Questions
What is clinical trial NCT00723099 about?
NCT00723099 is a clinical study titled "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer". This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps...
What is the current status of trial NCT00723099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2008-06-25. Estimated completion is 2018-07-31.
What conditions does trial NCT00723099 study?
This clinical trial studies the following conditions: Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT00723099?
The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Fludarabine Phosphate (DRUG), Cyclosporine (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00723099?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723099 being conducted?
This trial has 6 study locations across Colorado, Utah, Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.